Multicenter Publications

Multicenter	Afkarian, Maryam, et al. “Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data”. 2019. Diabetes Care, vol. 42, no. 8, 2019, pp. 1454–1463.	DOI PubMed PMC	Michigan
Multicenter		DOI PubMed PMC	Multicenter	Afkarian, Maryam, et al. “Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data”. 2019. Diabetes Care, vol. 42, no. 8, 2019, pp. 1454–1463.	DOI PubMed PMC	Joslin
Multicenter	Jang, Insook, et al. “PDIA1/P4HB/Is/Required/for/Efficient/Proinsulin/Maturation/and/ß/Cell/Health/in/Response/to/Diet/Induced/Obesity”. 2019. ELife, vol. 8, 2019.	DOI PubMed PMC	Michigan
Multicenter		DOI PubMed PMC	Multicenter	Jang, Insook, et al. “PDIA1/P4HB/Is/Required/for/Efficient/Proinsulin/Maturation/and/ß/Cell/Health/in/Response/to/Diet/Induced/Obesity”. 2019. ELife, vol. 8, 2019.	DOI PubMed PMC	UCSD-UCLA
Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Indiana
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Chicago
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Washington
			Multicenter	Consortium, RISE. “Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes”. 2019. Diabetes Care, vol. 42, no. 9, 2019, pp. 1742–1751.	DOI PubMed PMC	Yale
Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Indiana
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Chicago
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Washington
			Multicenter	Consortium, RISE, and RISE Consortium Investigators. “Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults”. 2019. Diabetes, vol. 68, no. 8, 2019, pp. 1670–1680.	DOI PubMed PMC	Yale